In the last 12 hours, the most substantive industry-relevant development is Pharming Group’s preliminary Q1 2026 results. The company reported total revenues of US$72.4 million (down 8% year-on-year), with RUCONEST® at US$58.4 million (down 15%) attributed to anticipated inventory drawdowns and a planned exit from non-U.S. markets. Offsetting this, Joenja® revenue rose 34% to US$14.1 million, driven by patient uptake, and Pharming reiterated 2026 revenue guidance of US$405–US$425 million. The update also highlights ongoing regulatory momentum for Joenja® (Japan approval and a positive CHMP opinion for APDS), alongside FDA resubmissions for pediatric dosing tiers, and a scheduled conference call.
Also in the last 12 hours, coverage is lighter and more mixed in relevance to Liechtenstein’s industrial/financial ecosystem: a sports-focused piece on Bristol Rovers’ 2025/26 season player ratings, and a commentary on World Press Freedom Day and the state of global press freedom. The remaining “last 12 hours” items are more editorial than policy or market-moving, so they provide limited direct continuity for industry themes.
From 12 to 72 hours ago, the coverage becomes more policy- and market-oriented, with several items that indirectly matter for cross-border business conditions. EU travel and border administration appears repeatedly: Italy and Portugal are described as preparing to scrap new EU border checks after Greece’s suspension of EES biometric requirements for UK tourists, with concerns raised that abandoning checks could undermine the broader EES rollout. In parallel, EU-level regulatory coordination is covered via the European Commission welcoming approval of revised social security coordination rules, aimed at reducing administrative burdens and improving protection for people working or living across EU borders—an issue that can affect labor mobility and cross-border company operations.
Across the broader 7-day window, there is also clear continuity around Liechtenstein-adjacent finance and trade themes. A CEO Insight supplement includes an interview with Simon Tribelhorn of the Liechtenstein Bankers Association, framing Liechtenstein’s positioning around legal certainty, cross-border capability, and balancing innovation (including digital assets and sustainability) with trust and regulatory strength. On the trade side, multiple articles discuss EU external economic policy and market access dynamics—such as the “Made in Europe” law concept tied to an economic showdown with China, and the Mercosur–EU trade deal entering provisional application with tariff cuts on thousands of products—while sanctions enforcement against Russia is also highlighted as being intensified with coordination including Liechtenstein.
Overall, the most concrete “industry” signal in the most recent window is Pharming’s Q1 performance and regulatory pathway for Joenja®, while the rest of the latest coverage is dominated by travel/border administration and broader geopolitical/economic commentary. The evidence is strong for Pharming’s near-term corporate trajectory, but comparatively sparse for any single Liechtenstein-specific industrial event in the last 12 hours.